Login / Signup

Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: A phase I, dose escalation, and expansion study.

Andrea Wang-GillamKian-Huat LimRobert R McWilliamsRama SureshAlbert C LockhartAmberly BrownMarcus A BredenJad I BelleJohn M HerndonSavannah J BognerKatrina S PedersenBenjamin TanNicholas BoiceAbhi AcharyaMina AbdianniaFeng GaoHarry H YoonMojun ZhuNikolaos A TrikalinosLee RatnerOlivia AranhaWilliam G HawkinsBrett H HerzogDavid G DeNardo
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The combination of defactinib, pembrolizumab, and gemcitabine was well-tolerated and safe, had promising preliminary efficacy and showed biomarker activity in infiltrative T lymphocytes. Efficacy of this strategy may require incorporation of more potent chemotherapy in future studies.
Keyphrases